Compare Biogen Inc (BIIB) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Grab Holdings Ltd. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Grab Holdings Ltd. trades at $3.61 (market cap $15.26B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| BIIB | GRAB | |
|---|---|---|
Market Cap | $30.13B | $15.26B |
Sector | Health | Technology |
52-Week High | $216.63 | $6.45 |
52-Week Low | $128.93 | $3.27 |
Enterprise Value | $37.20B | $10.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
GRAB trades at $3.605, down 1.77% today, but maintains a bullish technical trend. The company reported strong Q2 2026 earnings, beating estimates with $0.06 EPS, and raised full-year revenue guidance to 22-23% growth. Positive analyst sentiment includes an average price target of $5.86, implying 58% upside. Fundamentals show improving profitability, with net income turning positive in 2025 at $268 million and margins expanding.
Outlook is positive given earnings momentum and raised guidance, but risks include high valuation multiples, insider selling, and competitive pressures in Southeast Asia. The stock offers growth potential if execution continues, yet investors should weigh valuation against profitability sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
